Asia Pacific Psychedelic Drugs Market
市场规模（十亿美元）
CAGR :
% 
USD
27.24 Million
USD
63.70 Million
2021
2029
 Forecast Period |
2022 –2029 |
 Market Size (Base Year) |
USD 27.24 Million |
 Market Size (Forecast Year) |
USD 63.70 Million |
 CAGR |
% |
| Major Markets Players |
亚太迷幻药市场，按来源（合成与天然）、类型（致幻剂、解离剂及其他）、药物（γ-羟基丁酸、氯胺酮、裸盖菇素及其他）、用途（发作性睡病、难治性抑郁症、重度抑郁症、阿片类药物成瘾、创伤后应激障碍及其他）、给药途径（口服、吸入、注射）、最终用户（医院、专科诊所、家庭护理及其他）、分销渠道（医院药房、零售药房、网上药房）划分，行业趋势及预测至 2029 年。
亚太地区迷幻药市场分析与洞察
迷幻药涉及多种化学物质，包括麦角酸二乙酰胺 (LSD) 和从植物中提取的化学物质。这些药物能够改变或增强感官知觉、思维过程、能量水平，据报道还能促进精神体验。
迷幻药可分为共情药和解离药（如苯基环己基哌啶 (PCP)）和血清素药（经典致幻剂），如 LSD。这两种迷幻药都会引起幻觉和感觉，此外，解离药会使人失去对自己身体或环境的控制，使他们感到与世隔绝。根据来源，迷幻药分为天然和合成两类。
这些药物广泛应用于治疗重度抑郁症、创伤后应激障碍、惊恐障碍、难治性抑郁症和阿片类药物成瘾等。迷幻药还有其他几个名字，例如麦角酸衍生物 (LSD) 也被称为吸墨纸、点、糖、酸、旅行和窗格，氯胺酮也被称为维生素 K、肿块、绿色、K/特殊 K、紫色和超酸，PCP 也被称为天使/天使尘、船/爱之船、和平、杀手杂草、超级草和臭氧。
亚太地区迷幻药市场预计将在 2022 年至 2029 年的预测期内实现市场增长。Data Bridge Market Research 分析称，在 2022 年至 2029 年的预测期内，该市场将以 11.3% 的复合年增长率增长，预计到 2029 年将从 2021 年的 2724 万美元增至 6370 万美元。
|
报告指标 |
细节 |
|
预测期 |
2022 至 2029 年 |
|
基准年 |
2021 |
|
历史岁月 |
2020 (可定制为 2019-2014) |
|
定量单位 |
收入（百万美元），定价（美元） |
|
涵盖的领域 |
按来源（合成和天然）、类型（共情剂、解离剂和其他）、药物（γ-羟基丁酸、氯胺酮、裸盖菇素等）、用途（发作性睡病、难治性抑郁症、重度抑郁症、阿片类药物成瘾、创伤后应激障碍等）、给药途径（口服、吸入、注射）、最终用户（医院、专科诊所、家庭护理、其他）、分销渠道（医院药房、零售药房、网上药房） |
|
覆盖国家 |
印度、澳大利亚、韩国、新加坡、马来西亚 |
|
涵盖的市场参与者 |
在市场上交易的主要公司包括 Janssen Global Services, LLC（强生服务公司的子公司）、辉瑞公司、F. Hoffmann-La Roche Ltd 等 |
市场定义
迷幻药涉及多种化学物质，包括麦角酸二乙酰胺 (LSD) 和从植物中提取的化学物质。这些药物能够改变或增强感官知觉、思维过程、能量水平，据报道还能促进精神体验。
迷幻药可分为共情药和解离药（如苯基环己基哌啶 (PCP)）和血清素药（经典致幻剂），如 LSD。这两种迷幻药都会引起幻觉和感觉，此外，解离药会使人失去对自己身体或环境的控制，使他们感到与世隔绝。根据来源，迷幻药分为天然和合成两类。
这些药物广泛应用于治疗重度抑郁症、创伤后应激障碍、惊恐障碍、难治性抑郁症和阿片类药物成瘾等。迷幻药还有其他几个名字，例如麦角酸衍生物 (LSD)，也称为吸墨纸、点、糖、酸、旅行和窗格，氯胺酮也称为维生素 K、肿块、绿色、K/特殊 K、紫色和超酸，PCP 也称为天使/天使尘、船/爱之船、和平、杀手杂草、超级草和臭氧。
迷幻药市场动态
驱动程序
-
正在进行的临床试验
重度抑郁症已成为现代世界健康危机的严重问题。临床试验的开始是为了测试处于临床试验特定阶段的指定药物的安全性和有效性。抑郁症与大多数其他慢性疾病相比，与畸形的关系更为密切，因此它是死亡的风险因素。大多数抑郁症患者无法通过抗抑郁治疗完全缓解症状。已经进行了某些临床试验来研究其对身体的疗效。在各个地区进行的临床试验将导致药物快速获批、药物组合增强、迷幻药在康复中心的分发以及对药物治疗的认识提高，而这反过来又有望成为市场增长的动力。
-
产品批准数量上升
迷幻药的批准取决于许多因素，但至关重要的因素是主要医疗机构的批准。美国食品药品管理局是美国药品审批的主要机构，该中央机构决定医疗药物是否最终会到达患者手中。下面提供的是经过 FDA 审查的既定医学研究的临床数据，旨在评估开发的药物化合物或产品作为特定精神疾病治疗的可行性。产品批准的增加将导致药物在国内和国际国家的分销增加，安全性提高。这将为市场带来积极的增长。
机会
-
即将建成的康复中心
即将建成的康复中心（也称为患者康复医院）将确保及时治疗患有创伤后应激障碍（PTSD）和焦虑相关疾病的患者。这些康复中心提供有效的治疗方法，并允许患者使用先进的药物，从而改善患者的整体康复效果。它还将致力于为需要麻醉治疗的患者提供治疗，包括复杂手术、骨科、神经科、肌肉骨骼等，以稳定急性病情。
此外，迷幻药研发活动的不断增加将为 2022-2029 年预测期内的迷幻药市场提供结构完整性和未来机会。
克制/挑战
- 迷幻药专利到期
然而，部分公司的迷幻药专利到期将阻碍迷幻药市场的增长速度。此外，在上述预测期内，严格的规则和法规将进一步挑战市场。
本迷幻药市场报告详细介绍了最新发展、贸易法规、进出口分析、生产分析、价值链优化、市场份额、国内和本地市场参与者的影响，分析了新兴收入来源、市场法规变化、战略市场增长分析、市场规模、类别市场增长、应用领域和主导地位、产品批准、产品发布、地域扩展、市场技术创新等方面的机会。如需了解有关迷幻药市场的更多信息，请联系 Data Bridge Market Research 获取分析师简报，我们的团队将帮助您做出明智的市场决策，实现市场增长。
COVID-19 对迷幻药市场的影响
COVID-19 对市场产生了积极影响。疫情期间的封锁和隔离使疾病管理和服药依从性变得复杂。因此，世界人口中各种治疗药物的使用量大幅增加。因此，疫情对这个市场产生了积极影响。
最新动态
- 2020 年 8 月，杨森制药公司获批其 Spravato 鼻喷雾剂用于治疗有自杀倾向的人。由于大约 11% 至 12% 的美国人患有导致他们自杀的重度抑郁症，这项批准为这些患者提供了一种卓越的治疗方法，并为公司创造更多收入铺平了道路。
- 2020 年 1 月，Jazz Pharmaceuticals, Inc. 获得了 solriamfetol (Sunosi) 的上市许可，该药物用于治疗患有嗜睡症的成人白天过度嗜睡。此项授权使该公司能够增强产品分销网络并在市场上创造更多收入
亚太迷幻药市场范围
亚太迷幻药市场细分为来源、类型、药物、应用、给药途径、最终用户和分销渠道。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，以便做出战略决策，确定核心市场应用。
来源
- 合成的
- 自然的
根据来源，亚太迷幻药市场分为合成迷幻药和天然迷幻药。
类型
- 共情因素
- 解离性药物
- 其他的
根据类型，亚太地区的迷幻药市场分为共情剂、分离剂和其他类。
药物
- γ-羟基丁酸
- 氯胺酮
- 裸盖菇素
- 其他的
根据药物类型，亚太地区迷幻药市场分为γ-羟基丁酸、氯胺酮、裸盖菇素和其他药物。
应用
- 嗜睡症，
- 难治性抑郁症
- 重度抑郁症
- 鸦片成瘾
- 创伤后应激障碍
- 其他的
根据应用，亚太地区迷幻药市场分为发作性睡病、难治性抑郁症、重度抑郁症、阿片类药物成瘾、创伤后应激障碍等。
给药途径
- 口服
- 吸入
- 注射剂
根据给药途径，亚太地区迷幻药市场分为口服、吸入和注射。
最终用户
- 医院
- 专科诊所
- 家庭护理
- 其他的
根据最终用户，亚太迷幻药市场分为医院、专科诊所、家庭护理和其他。
分销渠道
- 医院药房
- 零售药店
- 网上药店
根据分销渠道，亚太迷幻药市场分为医院药房、零售药房和网上药房。
迷幻药市场区域分析/见解
对迷幻药市场进行了分析，并按国家、来源、类型、药物、应用、给药途径、最终用户和分销渠道提供了市场规模洞察和趋势。
该迷幻药报告涉及的国家包括印度、澳大利亚、韩国、新加坡和马来西亚。
印度在迷幻药市场的市场份额和市场收入方面占据主导地位，并将在预测期内继续保持主导地位。这是因为该地区越来越多人接受迷幻药治疗抑郁症，而且快速的研究发展也推动了市场的发展。
报告的国家部分还提供了影响单个市场因素和市场法规变化的信息，这些因素和变化会影响市场的当前和未来趋势。新旧销售、国家人口统计、疾病流行病学和进出口关税等数据点是预测单个国家市场情况的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了全球品牌的存在和可用性以及它们因本土和国内品牌的激烈竞争而面临的挑战以及销售渠道的影响。
竞争格局和迷幻药 份额分析
迷幻药市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对迷幻药市场的关注有关。
迷幻药市场的一些主要参与者包括杨森全球服务有限公司（强生服务公司的子公司）、辉瑞公司、罗氏公司等。
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。DBMR 研究团队使用的关键研究方法是数据三角测量，涉及数据挖掘、数据变量对市场影响的分析以及主要（行业专家）验证。除此之外，数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、亚太地区与地区和供应商份额分析。如有进一步询问，请要求分析师致电
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA PACIFIC PSYCHEDELIC DRUGS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PIPELINE ANALYSIS
4.2 PESTEL ANALYSIS
4.3 PORTER'S FIVE FORCES MODEL
5 REGULATORY FRAMEWORK: ASIA PACIFIC PSYCHEDELIC DRUGS MARKET
5.1 REGULATORY SCENARIO IN THE U.S.
5.2 REGULATORY SCENARIO IN THE U.K.
5.3 REGULATORY SCENARIO IN INDIA
5.4 REGULATORY SCENARIO IN UAE
5.5 REGULATORY SCENARIO IN AFRICA
5.6 REGULATORY SCENARIO IN BRAZIL
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 GROWING ACCEPTANCE OF PSYCHEDELIC DRUGS TO TREAT DEPRESSION
6.1.2 INCREASING PREVALENCE OF DEPRESSION AND MENTAL DISORDERS
6.1.3 RISING AWARENESS TOWARD MENTAL HEALTH
6.1.4 ONGOING CLINICAL TRIALS
6.1.5 RISE IN PRODUCT APPROVALS
6.2 RESTRAINTS
6.2.1 STRINGENT REGULATIONS FOR PSYCHEDELIC DRUGS
6.2.2 HIGH COST OF PSYCHEDELIC DRUGS
6.2.3 PATENT EXPIRY OF PSYCHEDELIC DRUGS
6.3 OPPORTUNITIES
6.3.1 INCREASING R&D ACTIVITIES IN PSYCHEDELIC DRUGS
6.3.2 BREAKTHROUGH THERAPY DESIGNATION BY REGULATORY AUTHORITY
6.3.3 UPCOMING REHABILITATION CENTERS
6.3.4 AVAILABILITY OF CERTIFIED HEALTHCARE PROFESSIONALS
6.4 CHALLENGES
6.4.1 SIDE EFFECTS ASSOCIATED WITH PSYCHEDELIC DRUGS
6.4.2 RISE IN ILLEGAL ALTERNATIVES
6.4.3 AVAILABILITY OF OTHER TREATMENT OPTIONS
7 COVID-19 IMPACT ON THE ASIA PACIFIC PSYCHEDELIC DRUGS MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT ON DEMAND
7.3 IMPACT ON SUPPLY CHAIN
7.4 STRATEGIC DECISIONS FOR MANUFACTURERS
7.5 CONCLUSION
8 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET, BY TYPE
8.1 OVERVIEW
8.2 EMPATHOGENS
8.3 DISSOCIATIVES
8.4 OTHERS
9 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET, BY SOURCE
9.1 OVERVIEW
9.2 SYNTHETIC
9.3 NATURAL
10 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET, BY DRUGS
10.1 OVERVIEW
10.2 GAMMA-HYDROXYBUTYRIC ACID
10.3 KETAMINE
10.4 PSILOCYBIN
10.5 OTHERS
11 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 NARCOLEPSY
11.3 TREATMENT RESISTANT DEPRESSION
11.4 MAJOR DEPRESSIVE DISORDER
11.5 OPIATE ADDICTION
11.6 POST-TRAUMATIC STRESS DISORDER
11.7 OTHERS
12 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 ORAL
12.3 INHALATION
12.4 INJECTABLE
13 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS
13.3 SPECIALTY CLINICS
13.4 HOMECARE
13.5 OTHERS
14 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 HOSPITALS PHARMACY
14.3 RETAIL PHARMACY
14.4 ONLINE PHARMACY
15 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET, BY REGION
15.1 ASIA-PACIFIC
15.1.1 INDIA
15.1.2 AUSTRALIA
15.1.3 SOUTH KOREA
15.1.4 SINGAPORE
15.1.5 MALAYSIA
16 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 JAZZ PHARMACEUTICALS, INC.
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 PFIZER INC.
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 F. HOFFMANN- LA ROCHE LTD
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENT
18.4 JANSSEN ASIA PACIFIC SERVICES, LLC (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
18.4.1 COMPANY SNAPSHOT
18.4.2 COMPANY SHARE ANALYSIS
18.4.3 PRODUCT PORTFOLIO
18.4.4 RECENT DEVELOPMENT
18.5 AVADEL
18.5.1 COMPANY SNAPSHOT
18.5.2 PRODUCT PORTFOLIO
18.5.3 RECENT DEVELOPMENT
18.6 CELON PHARMA SA
18.6.1 COMPANY SNAPSHOT
18.6.2 PRODUCT PORTFOLIO
18.6.3 RECENT DEVELOPMENT
18.7 COMPASS
18.7.1 COMPANY SNAPSHOT
18.7.2 PRODUCT PORTFOLIO
18.7.3 RECENT DEVELOPMENTS
18.8 CYBIN CORP.
18.8.1 COMPANY SNAPSHOT
18.8.2 PRODUCT PORTFOLIO
18.8.3 RECENT DEVELOPMENTS
18.9 ENTHEON BIOMEDICAL CORP
18.9.1 COMPANY SNAPSHOT
18.9.2 PRODUCT PORTFOLIO
18.9.3 RECENT DEVELOPMENT
18.1 GH RESEARCH
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENT
18.11 HIKMA PHARMACEUTICALS PLC
18.11.1 COMPANY SNAPSHOT
18.11.2 REVENUE ANALYSIS
18.11.3 PRODUCT PORTFOLIO
18.11.4 RECENT DEVELOPMENTS
18.12 NRX PHARMACEUTICALS, INC.
18.12.1 COMPANY SNAPSHOT
18.12.2 PRODUCT PORTFOLIO
18.12.3 RECENT DEVELOPMENT
18.13 PHARMATHER HOLDINGS LTD.
18.13.1 COMPANY SNAPSHOT
18.13.2 PRODUCT PORTFOLIO
18.13.3 RECENT DEVELOPMENT
18.14 VERRIAN
18.14.1 COMPANY SNAPSHOT
18.14.2 PRODUCT PORTFOLIO
18.14.3 RECENT DEVELOPMENT
18.15 USONAINSTITUTE.ORG
18.15.1 COMPANY SNAPSHOT
18.15.2 PRODUCT PORTFOLIO
18.15.3 RECENT DEVELOPMENT
19 QUESTIONNAIRE
20 RELATED REPORTS
表格列表
TABLE 1 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET, PIPELINE ANALYSIS
TABLE 2 PSYCHEDELICS RESEARCH STUDIES, IN EUROPE
TABLE 3 MENTAL ILLNESS IN THE U.S. ADULTS, IN 2020
TABLE 4 MENTAL DISORDERS, IN THE U.S. ADULTS, IN 2020
TABLE 5 DRUG DEVELOPMENT PATHWAY FOR FDA APPROVAL OF NEW MEDICATIONS
TABLE 6 THE 1971 UN CONVENTION ON PSYCHOTROPIC SUBSTANCES
TABLE 7 MAGIC MUSHROOMS PRICES FOR RESEARCHERS, IN THE U.S.
TABLE 8 COST OF PSYCHEDELIC DRUGS
TABLE 9 PSYCHEDELIC DRUGS R&D ACTIVITIES
TABLE 10 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 11 ASIA PACIFIC EMPATHOGENS IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 ASIA PACIFIC DISSOCIATIVES IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 ASIA PACIFIC OTHERS IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 15 ASIA PACIFIC SYNTHETIC IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 ASIA PACIFIC NATURAL IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)
TABLE 18 ASIA PACIFIC GAMMA-HYDROXYBUTYRIC ACID IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 ASIA PACIFIC KETAMINE IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 ASIA PACIFIC PSILOCYBIN IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 ASIA PACIFIC OTHERS IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 23 ASIA PACIFIC NARCOLEPSY IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 ASIA PACIFIC TREATMENT RESISTANT DEPRESSION IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 ASIA PACIFIC MAJOR DEPRESSIVE DISORDER IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 ASIA PACIFIC OPIATE ADDICTION IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 ASIA PACIFIC POST-TRAUMATIC STRESS DISORDER IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 ASIA PACIFIC OTHERS IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 30 ASIA PACIFIC ORAL IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 ASIA PACIFIC INHALATION IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 ASIA PACIFIC INJECTABLE IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 34 ASIA PACIFIC HOSPITALS IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 ASIA PACIFIC SPECIALTY CLINICS IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 ASIA PACIFIC HOMECARE IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 ASIA PACIFIC OTHERS IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 39 ASIA PACIFIC HOSPITALS PHARMACY IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 40 ASIA PACIFIC RETAIL PHARMACY IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 41 ASIA PACIFIC ONLINE PHARMACY IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 42 ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 43 ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 44 ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 45 ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)
TABLE 46 ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 47 ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 48 ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 49 ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 50 INDIA PSYCHEDELIC DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 51 INDIA PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 52 INDIA PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)
TABLE 53 INDIA PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 54 INDIA PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 55 INDIA PSYCHEDELIC DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 56 INDIA PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 57 AUSTRALIA PSYCHEDELIC DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 58 AUSTRALIA PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 59 AUSTRALIA PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)
TABLE 60 AUSTRALIA PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 61 AUSTRALIA PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 62 AUSTRALIA PSYCHEDELIC DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 63 AUSTRALIA PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 64 SOUTH KOREA PSYCHEDELIC DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 65 SOUTH KOREA PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 66 SOUTH KOREA PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)
TABLE 67 SOUTH KOREA PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 68 SOUTH KOREA PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 69 SOUTH KOREA PSYCHEDELIC DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 70 SOUTH KOREA PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 71 SINGAPORE PSYCHEDELIC DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 72 SINGAPORE PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 73 SINGAPORE PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)
TABLE 74 SINGAPORE PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 75 SINGAPORE PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 76 SINGAPORE PSYCHEDELIC DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 77 SINGAPORE PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 78 MALAYSIA PSYCHEDELIC DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 MALAYSIA PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 80 MALAYSIA PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)
TABLE 81 MALAYSIA PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 82 MALAYSIA PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 83 MALAYSIA PSYCHEDELIC DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 84 MALAYSIA PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET : DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: MULTIVARIATE MODELLING
FIGURE 7 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: END USER COVERAGE GRID
FIGURE 10 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: SEGMENTATION
FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE THE ASIA PACIFIC PSYCHEDELIC DRUGS MARKET GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 RISING AWARENESS TOWARDS MERANTAL HEALTH DRIVING THE ASIA PACIFIC PSYCHEDELIC DRUGS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 EMPATHOGENS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC PSYCHEDELIC DRUGS MARKET IN 2022 & 2029
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC PSYCHEDELIC DRUGS MARKET
FIGURE 16 MENTAL ILLNESS AMONG THE U.S. ADULTS, IN 2020, (IN %), BY DEMOGRAPHIC GROUPS
FIGURE 17 MENTAL ILLNESS TREATMENT RATES AMONG THE U.S. ADULTS, IN 2020, (IN %), BY DEMOGRAPHIC GROUPS
FIGURE 18 MENTAL ILLNESS TREATMENT RATES AMONG THE U.S. ADULTS, IN 2020, (IN %), BY GENDER
FIGURE 19 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY TYPE, 2021
FIGURE 20 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 21 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 22 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 23 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY SOURCE, 2021
FIGURE 24 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY SOURCE, 2022-2029 (USD MILLION)
FIGURE 25 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY SOURCE, CAGR (2022-2029)
FIGURE 26 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY SOURCE, LIFELINE CURVE
FIGURE 27 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY DRUGS, 2021
FIGURE 28 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY DRUGS, 2022-2029 (USD MILLION)
FIGURE 29 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY DRUGS, CAGR (2022-2029)
FIGURE 30 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY DRUGS, LIFELINE CURVE
FIGURE 31 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY APPLICATION, 2021
FIGURE 32 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY APPLICATION, 2022-2029 (USD MILLION)
FIGURE 33 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 34 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 35 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 36 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
FIGURE 37 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 38 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 39 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY END USER, 2021
FIGURE 40 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 41 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY END USER, CAGR (2022-2029)
FIGURE 42 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY END USER, LIFELINE CURVE
FIGURE 43 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 44 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 45 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 46 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 47 ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET: SNAPSHOT (2021)
FIGURE 48 ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET: BY COUNTRY (2021)
FIGURE 49 ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 50 ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 51 ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET: BY TYPE (2022-2029)
FIGURE 52 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: COMPANY SHARE 2021 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
